These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections. Niki Y; Tamada S; Nakabayashi M; Soejima R Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385 [No Abstract] [Full Text] [Related]
6. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic. Lipsky BA; Dorr MB; Magner DJ; Talbot GH Clin Ther; 1999 Jan; 21(1):148-59. PubMed ID: 10090432 [TBL] [Abstract][Full Text] [Related]
7. Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients. Spivey IM Clin Pharm; 1993 Jun; 12(6):452-8. PubMed ID: 8403817 [No Abstract] [Full Text] [Related]
8. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Goa KL; Bryson HM; Markham A Drugs; 1997 Apr; 53(4):700-25. PubMed ID: 9098667 [TBL] [Abstract][Full Text] [Related]
9. Two new fluoroquinolones. Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502 [No Abstract] [Full Text] [Related]
10. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment? Norrby SR J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879 [No Abstract] [Full Text] [Related]
11. Safety profile of sparfloxacin in the treatment of respiratory tract infections. Rubinstein E J Antimicrob Chemother; 1996 May; 37 Suppl A():145-60. PubMed ID: 8737134 [TBL] [Abstract][Full Text] [Related]
12. New generations of quinolones: with particular attention to levofloxacin. Ambrose PG; Owens RC; Quintiliani R; Nightingale CH Conn Med; 1997 May; 61(5):269-72. PubMed ID: 9197076 [No Abstract] [Full Text] [Related]
13. Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Wadworth AN; Goa KL Drugs; 1991 Dec; 42(6):1018-60. PubMed ID: 1724637 [TBL] [Abstract][Full Text] [Related]
14. Sparfloxacin: potential clinical and economic impact in the treatment of respiratory infections. Stein GE; Havlichek DH Pharmacotherapy; 1997; 17(6):1139-47. PubMed ID: 9399598 [TBL] [Abstract][Full Text] [Related]
15. [How are quinolones used in clinical practice? Gyrase antagonists from the viewpoint of the hospital pharmacist]. Schurz JK Pharm Unserer Zeit; 2001; 30(5):400-5. PubMed ID: 11575176 [No Abstract] [Full Text] [Related]
16. Laboratory and clinical study of balofloxacin (Q-35), a new fluoroquinolone, in urinary tract infection. Suzuki K; Horiba M; Ishikawa K; Katoh S; Naide Y; Yanaoka M; Andoh S Drugs; 1995; 49 Suppl 2():376-8. PubMed ID: 8549367 [No Abstract] [Full Text] [Related]
17. The fluoroquinolones after ciprofloxacin and ofloxacin. Hooper DC Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519 [No Abstract] [Full Text] [Related]
18. The fluoroquinolones. Walker RC Mayo Clin Proc; 1999 Oct; 74(10):1030-7. PubMed ID: 10918871 [TBL] [Abstract][Full Text] [Related]
19. [Moxifloxacin--a novel antimicrobial preparation for treatment of respiratory infections]. Iakovlev SV; Polushkina NR; Iakovlev VP Ter Arkh; 2001; 73(11):15-22. PubMed ID: 11806197 [No Abstract] [Full Text] [Related]
20. [The role of respiratory quinolone in treatment of respiratory tract infections: focusing on gatifloxacin]. Kohno S; Watanabe A; Matsushima T Jpn J Antibiot; 2002 Jun; 55(3):247-58. PubMed ID: 12199109 [No Abstract] [Full Text] [Related] [Next] [New Search]